Literature DB >> 16332969

ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL).

Sarah J Richardson1, Christine Matthews, Mark A Catherwood, H Denis Alexander, B Sean Carey, Joanna Farrugia, Anne Gardiner, Sarah Mould, David Oscier, J Adrian Copplestone, Archibald G Prentice.   

Abstract

Molecular markers like IgV(H) mutational status, chromosomal abnormalities, and CD38 and ZAP-70 expression have prognostic value in B-cell chronic lymphocytic leukemia (B-CLL). These may be pathogenetic because of the coincidental expression of ZAP-70 and increased B-cell receptor (BCR) signaling and the signaling function of CD38 in CLL. This study shows that ZAP-70(+) CLL B cells respond in vitro more readily than ZAP-70(-) CLL and normal B cells to chemokine migratory signals through enhanced surface CCR7 expression (P = .009; P < .001) and increased responsiveness to its ligands CCL19 and CCL21, demonstrated by F-actin polymerization (P < .05) and cellular migration (P < .01). In addition, ZAP-70(+) CLL cells exhibit sustained ERK phosphorylation/activation following stimulation with CXCL12 (SDF1-alpha, a survival factor produced by stromal cells) compared with ZAP-70(-) cells (P = .004). Following coculture with nurse-like cells, the survival of ZAP-70(+) but not ZAP-70(-) CLL cells is significantly enhanced by the addition of CXCL12 (P < .05), an effect that is partially blocked by the MEK inhibitor PD98059. These advantageous migratory and survival responses may promote easier access to and greater proliferation in pseudo-germinal centers and explain in part the more progressive nature of ZAP-70(+) disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16332969     DOI: 10.1182/blood-2005-04-1718

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

Review 1.  The B-cell receptor signaling pathway as a therapeutic target in CLL.

Authors:  Jennifer A Woyach; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

2.  Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.

Authors:  Davorka Messmer; Jessie-F Fecteau; Morgan O'Hayre; Ila S Bharati; Tracy M Handel; Thomas J Kipps
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

3.  Tailoring of chronic lymphatic leukemia therapy.

Authors:  Ashraf M Elhefni
Journal:  Am J Blood Res       Date:  2013-08-19

4.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Authors:  Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

5.  ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia.

Authors:  Liguang Chen; Lang Huynh; John Apgar; Li Tang; Laura Rassenti; Arthur Weiss; Thomas J Kipps
Journal:  Blood       Date:  2007-11-29       Impact factor: 22.113

6.  CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells.

Authors:  Rajendra N Damle; Sonal Temburni; Carlo Calissano; Sophia Yancopoulos; Taraneh Banapour; Cristina Sison; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2007-08-07       Impact factor: 22.113

7.  Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation.

Authors:  Silvia Deaglio; Fabio Malavasi
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

Review 8.  Targeting the B cell receptor pathway in chronic lymphocytic leukemia.

Authors:  Matthew S Davids; Jennifer R Brown
Journal:  Leuk Lymphoma       Date:  2012-12

Review 9.  B cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Jan A Burger; Nicholas Chiorazzi
Journal:  Trends Immunol       Date:  2013-08-05       Impact factor: 16.687

10.  Cell Trafficking in Chronic Lymphocytic Leukemia.

Authors:  Matthew S Davids; Jan A Burger
Journal:  Open J Hematol       Date:  2012-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.